{"schema_version":"secwatch.filing_event.v1","accession":"0001818331-24-000021","form_type":"8-K","ticker":"WGS","cik":"0001818331","company_name":"GeneDx Holdings Corp.","filed_at":"2024-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.330535+00:00","generated_at":"2026-06-03T05:42:10.414290+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"GeneDx Q1 exome/genome revenue up 96% YoY; raises FY 2024 guidance to $235-245M","bullets":["Revenue from continuing ops $61.5M (+51% YoY); exome/genome revenue $44.0M (+96% YoY).","Adjusted gross margin expanded to 61% from 34% YoY; exome/genome margin above 65%.","Adjusted net loss narrowed to $8.5M (83% YoY improvement); GAAP net loss $20.2M.","Cash burn reduced 71% YoY to $17.2M; cash position $113.9M as of March 31.","Raised FY 2024 revenue guidance to $235-245M; reiterate path to profitability in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001818331-24-000021","json":"https://secwatch.observer/filing/0001818331-24-000021.json","markdown":"https://secwatch.observer/filing/0001818331-24-000021.md","text":"https://secwatch.observer/filing/0001818331-24-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818331/000181833124000021/0001818331-24-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818331/000181833124000021/wgs-20240429.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T05:42:10.414290+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4be3014127c6528e7905e9e224fb2b99da0bee2a","claim":"GeneDx Holdings Corp. reported quarter ended March 31, 2024 results: revenue $61.5 million, net income $8.5 million. Guidance raised.","evidence_excerpt":"and reiterate our expectation to reach profitability in 2025.” First Quarter 2024 Financial Results (Unaudited) 1,2 Revenues • Revenues from continuing operations grew to $61.5 million, an increase of 51% year-over-year and 6% sequentially. ◦ Total company revenues were $62.4 million. • Exome and genome test revenue grew to $44.0 million, an increase of 96%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818331/000181833124000021/0001818331-24-000021-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2024"},{"label":"Revenue","value":"$61.5 million"},{"label":"Net income","value":"$8.5 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}